AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT02296125

Public ClinicalTrials.gov record NCT02296125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer

Study identification

NCT ID: NCT02296125
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 674 participants

Conditions and interventions

Conditions

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 3, 2014 (Actual)
Primary completion: Jun 19, 2017 (Actual)
Completion: Nov 20, 2025 (Actual)
Last update posted: Apr 21, 2026

2014 – 2025

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Research Site	Anaheim	California	92801	—
Research Site	Santa Rosa	California	95403	—
Research Site	West Hills	California	91307	—
Research Site	Tampa	Florida	33612	—
Research Site	Atlanta	Georgia	30318	—
Research Site	Atlanta	Georgia	30322	—
Research Site	Marietta	Georgia	30060	—
Research Site	Louisville	Kentucky	40202	—
Research Site	Bethesda	Maryland	20817	—
Research Site	Boston	Massachusetts	02215	—
Research Site	Minneapolis	Minnesota	55407	—
Research Site	Lebanon	New Hampshire	03756	—
Research Site	Salisbury	North Carolina	28144	—
Research Site	Burlington	Vermont	05401	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 156 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02296125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 21, 2026 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02296125 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →